Animal models of disease are an indispensable tool to study the mechanisms of human disease development, as well as for drug screening and efficacy evaluations. Accurate disease animal models can accelerate the development of new drugs. To provide the highest-quality models to researchers, Cyagen continuously optimizes our gene editing technologies and recruits leading specialists to support your scientific innovation. Cyagen has established an animal platform for drug development, screening, or evaluation covering a wide range of disease studies, including cancer, immunity, endocrine, cardiovascular, neurological, and infectious diseases.
Cyagen can provide you with a variety of drug evaluation models along with phenotype analysis services – delivering reliable and expedient data reporting for your project.
With the rapid development of sequencing technology and gene therapy, more and more rare diseases have the opportunity to transition from bench to clinic in terms of understanding their pathogenic mechanisms and treatment methods. In this process, animal models that possess disease homology, phenotypic consistency, and drug predictability, especially genomically humanized mouse models, play an important role in advancing the study of disease mechanisms, drug target research, and drug efficacy evaluation. Leveraging the advantages of our gene editing platform, Cyagen has developed a series of rare disease models in mice, such as gene knockout, gene knock-in, point mutations, and humanized mice, accelerating the progress of rare disease drug efficacy verification.
In recent years, significant progress has been made in understanding the genetic factors underlying various ophthalmic diseases. The development of relevant animal models has played a crucial role in advancing preclinical research, including the study of disease mechanisms, drug target identification, and evaluation of treatment efficacy. Cyagen has created a series of gene-edited models for ophthalmic diseases, such as Leber Congenital Amaurosis 2 (LCA2), Leber Congenital Amaurosis 10 (LCA10), retinitis pigmentosa, retinal degeneration, age-related macular degeneration, and corneal endothelial dysfunction. These models exhibit well-defined phenotypic characteristics and offer stable and heritable genetic traits, making them valuable tools for various ophthalmology-related investigations.
With the aging of society and the prevalence of obesity, the incidence rate of metabolic diseases is increasing, which has posted a serious threat to human health. The most common metabolic diseases include obesity, type 2 diabetes mellitus due to insulin resistance and nonalcoholic fatty liver disease / nonalcoholic fatty hepatitis (nafld/nash).
Mouse tumor model is an indispensable tool for studying tumor development mechanism, drug screening and efficacy evaluation. Cyagen animal model platform for innovative drug research and development can provide various accurate tumor models, tumor cell line transplantation model and human tumor xenotransplantation model (CDX) according to your research needs. We can develop all kinds of subcutaneous, in situ or metastatic tumor models, and provide highly customized pharmacodynamic services for the corresponding models to meet your research needs.
Immunodeficient mice refer to the mice with defects or deletions of one or more immune components (B cells, T cells, NK cells, etc.) in the immune system caused by congenital genetic mutation or artificial methods. They play an increasingly important role in the research of immunity, tumor, stem cell and the treatment of infectious diseases. Congenital immunodeficiency mice are more commonly used in scientific research experiments, which are genetically deficient, such as nude mice, nod SCID and so on, and are often used as tumor model experimental animals. Severe immunodeficiency mice are widely used in the construction of humanized mice due to the lack of T, B and NK immune cells.